Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use

Biological Psychiatry

Volumn 42, Issue 2, 1997, Pages 144-146

  Abraham, Jacob T ^a,d   Brown, Richard ^b   Meltzer, Herbert Y ^c  

^a BROWN UNIVERSITY   (United States)

^b Columbia University ^*  (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Bipolar disorder; Clozapine; Paroxetine; Paroxysmal dykeinesia; Sumatriptan

Indexed keywords

CLOZAPINE; PAROXETINE; SUMATRIPTAN;

ADULT; ARTICLE; BIPOLAR DEPRESSION; CASE REPORT; DYSKINESIA; FEMALE; HUMAN; MIGRAINE; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; NEUROLOGIC EXAMINATION; PAROXETINE; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0030920146     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00248-5     Document Type: Article

References (36)

1. Anonymous (1993): Extrapyramidal symptoms associated with paroxetine. Curr Probl Pharmacovigilance 19:1.
2. Azmitia EC (1978): The serotonergic producing neurons of the midbrain median and dorsal raphe nuclei. In: Psychopharmacology, vol 9: Chemical Pathways in the Brain. New York: Plenum Press, pp 233-314.
3. Bacher NM, Ruskin P (1991): Addition of fluoxetine to treatment of schizophrenic patients. Am J Psychiatry 148:274-275.
4. Baldwin D, Fineberg N, Montgomery S (1991): Fluoxetine, fluvoxamine, and extrapyramidal tract disorders. Int Clin Psychopharmacol 6:51-58.
5. Black B, Uhde TW (1992): Acute dystonia and fluoxetine. J Clin Psychiatry 53:327.
6. Blier P, Bergeron R (1995): The safety of concomitant use of sumatriptan and antidepressant treatments. J Clin Psychopharmacol 15:106-109.
7. Blier P, de Montigny C, Chaput I (1990): A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence. J Clin Psychiatry 51(suppl):14-20.
8. Bouchard RH, Poucher E, Vincent P (1989): Fluoxetine and extrapyramidal side effects. Am J Psychiatry 146:1352-1353.
9. Budman CL, Bruun RD (1991): Persistent dyskinesia in a patient receiving fluoxetine. Am J Psychiatry 148:1403.
10. Casey DE (1983): Metaclopramide side effects. Ann Intern Med 98:673-674.
11. Casey DE (1989): Clozapine, neuroleptic-induced EPS, and tardive dyskinesia. Psychopharmacology 99(suppl):547-553.
12. Clow A, Theodorou A, Jenner P, Marsden CD (1980): Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur J Pharmacol 63:145-157.
13. Dave M (1992): Fluoxetine associated dystonia. Am J Psychiatry 151:149.
14. Davies J, Tonogrouch P (1978): Neuropharmacological effects of fluoxetine on the nigro-striatal and raphe-striatal system in the rat. Eur J Pharmacol 51:91-100.
15. Fallon BA, Liebowitz MR (1991): Fluoxetine and extrapyramidal symptoms in CNS lupus. J Clin Psychopharmacol 11: 147-148.
16. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS (1991): The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 31:291-294.
17. Hamilton MS, Opler LA (1992): Akathisia, suicidality, and fluoxetine. J Clin Psychiatry 53:401-406.
18. Jeste DV, Caliguiri MP (1993): Tardive dyskinesia. Schizophr Bull 19:303-315.
19. Jeste DV, Potkin SG, Feder S, Wyatt RJ (1979): Tardive dyskinesia - Reversible and persistent. Arch Gen Psychiatry 36:585-590.
20. Joseph AB, Young RR (1992): Movement Disorders in Neurology and Neuropsychiatry. Boston: Blackwell Scientific Publications.
21. Kane JM, Smith JM (1982): Tardive dyskinesia: Prevalence and risk factors. Arch Gen Psychiatry 39:473-481.
22. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J (1986): Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254-258.
23. Lapin RI, Auchincloss EL (1994): Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 331:1021-1022.
24. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J (1991): The effect of clozapine on tardive dyskinesia. Br J Psychiatry 158:503-510.
25. Meltzer HY (1995): Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3:64-75.
26. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC (1979): Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 45:165-175.
27. 2 pKi values. J Pharmacol Exp Ther 251:238-246.
28. Meltzer HY, Yamamoto B, Lowy MT, Stockmeier CA (1996): The mechanism of action of atypical antipsychotic drugs: An update. In: Watson SJ, Akil H, editors. Biology of Schizophrenia and Affective Disease - ARNMD Series. New York: Raven Press, pp 451-492.
29. Reccoppa L, et al (1990): Acute dystonia and fluoxetine. J Clin Psychiatry 51:487.
30. Shihabuddin L, Rapport D (1994): Sertraline and extrapyramidal side effects. Am J Psychiatry 151:288.
31. Stein MH (1991): Tardive dyskinesia in a patient taking haloperidol and fluoxetine. Am J Psychiatry 148:274-275.
32. Stoukides JA, Stoukides CA (1991): Extrapyramidal symptoms on discontinuation of fluoxetine. Am J Psychiatry 148:1263.
33. Tate J (1989): Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 146:399-400.
34. Westfall TC, Tittermary V (1982): Inhibition of the electrically induced release of (3H) dopamine by superfused rat striatal slices. Neurosci Lett 28:205-209.
35. Yamamoto BK, Pehek EA, Meltzer HY (1994): Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55(suppl B):8-14.
36. Yassa R, Camille Y, Belzile L (1987): Tardive dyskinesia in the course of antidepressant therapy: A prevalence study and a review of the literature. J Clin Psychopharmacol 7:243-246.